GP I down-regulated the p38MAPK signaling pathway in aortas. Aorta was sampled at day 22 (mono-dose groups) and day 43 (complex-dose groups) with ten aortas selected from each group after treatment and then assessed by real time PCR (GADPH was selected as the internal control) and Western Blotting (β-Tublin was selected as the internal control). A. Relative fold change in p38MAPK mRNA levels. B. Ratio of phosphorylated p38MAPK to p38MAPK protein. *
P < 0.05 vs. normal control; #
P < 0.05 vs. diabetic controls; @
P < 0.05 vs. reduced β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.